Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) Net Income towards Common Stockholders (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Net Income towards Common Stockholders for 7 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 45.79% to -$3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.4 million through Dec 2025, up 495.73% year-over-year, with the annual reading at $61.4 million for FY2025, 650.99% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$3.4 million at Strata Critical Medical, down from $67.1 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $67.1 million in Q3 2025, with the low at -$33.9 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$2.9 million, with a median of -$4.0 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders crashed 129806.39% in 2021, then surged 1726.11% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at $772000.0 in 2021, then crashed by 2096.76% to -$15.4 million in 2022, then tumbled by 120.18% to -$33.9 million in 2023, then surged by 93.04% to -$2.4 million in 2024, then crashed by 45.79% to -$3.4 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$3.4 million, $67.1 million, and -$3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.